MRK

Merck & Co., Inc. · Healthcare · Drug Manufacturers - General
$119.96
-0.19 (-0.16%)
Mkt Cap: 296.59B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield4.7%
Dividend YieldN/A
Market Cap296.59B
Volume8.36M
Recent News
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
zacks.com · 2026-04-14
Merck (MRK) Stock Sinks As Market Gains: Here's Why
zacks.com · 2026-04-13
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
businesswire.com · 2026-04-13
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
businesswire.com · 2026-04-13
Trump policies, China's biotech boom are ending Europe's pharma powerhouse era
cnbc.com · 2026-04-11
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
businesswire.com · 2026-04-10

Unlock the Full Deep Scan

9 AI agents analyze MRK across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →